OP016: Mini-COMET: Safety and efficacy of ≥97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa
David Kronn(New York Medical College), On behalf of the Mini-COMET investigators(Duke Medical Center), Yin‐Hsiu Chien(National Taiwan University Hospital), S. Grace Prakalapakorn(Duke University), James Davison(Great Ormond Street Hospital for Children NHS Foundation Trust), Satoko Kumada(Tokyo Metropolitan Neurological Hospital), Swathi Tammireddy, Priya S. Kishnani(Duke Medical Center), Xianzhang Meng(Sanofi (United States)), Kristina An Haack(Sanofi (France)), Alexander Broomfield(St Mary's Hospital), Hirotaka Ohki(Tokyo Metropolitan Children's Medical Center), Susan Sparks(Children's National), Si Houn Hahn(University of Washington), Anaïs Brassier(Hôpital Necker-Enfants Malades), Tianyue Zhou, Catherine Wilson(Loughborough University), François Labarthe(Université de Tours), Atef Zaher(Sanofi (United States))
Cited by 10
Related Papers
Biparental Inheritance of Mitochondrial DNA in Humans
|Proceedings of the National Academy of Sciences|2018|451
Glycogen Storage Disease Type III diagnosis and management guidelines
|Genetics in Medicine|2010|305
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
|Genetics in Medicine|2009|292
Schwannomatosis
|Neurology|1996|244
Targeted long-read sequencing identifies missing disease-causing variation
|The American Journal of Human Genetics|2021|239